Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions
CLINICAL NEUROLOGY AND NEUROSURGERY, vol.209, 2021 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 209
- Publication Date: 2021
- Doi Number: 10.1016/j.clineuro.2021.106889
- Journal Name: CLINICAL NEUROLOGY AND NEUROSURGERY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE
- Keywords: Abobotulinum toxin A, Onabotulinum toxin A, Dystonia, Dysport, Botox, Dose conversion ratio
- Dokuz Eylül University Affiliated: Yes
Abstract
Objectives: Onabotulinum toxin A (ONA, Botox (R)) and abobotulinum toxin A (ABO, Dysport (R)) are most frequently used in the treatment of movement disorders. The aim of this study was to identify the dose conversion ratio (ABO dose:ONA dose), comparative efficacy, and adverse events in patients who switched from ONA to ABO.